Subject: Du Pont Is Preparing To Enter New Areas And Take Some Risks
Date: Published: 9/14/84 40 lines
Source:  Wall Street Journal.  Copyright Dow Jones Inc. 

   Du Pont Is Preparing
   To Enter New Areas
   And Take Some Risks
    ---
   Unveils $85 Million Facility
   For Biotechnology Study
   To Gain Market Position
    ---
   By Alix M. Freedman
   Staff Reporter of The Wall Street Journal

   WILMINGTON, Del. -- Du Pont Co., determined to reduce its
dependence on petrochemicals, today unveils its Experimental
Station, an $85 million research facility devoted to health
and agricultural sciences.
   
[57 lines of text irrelevant to AIDS have been omitted -- sysop.]
 
   The biomedical effort will take longer to pay off,
particularly in the pharmaceutical area.  Currently, Du Pont's
prescription drug line has sales of about $150 million.
Company scientists are now doing research on drugs to treat
metabolic diseases, cancer and heart irregularities.
   Du Pont also is agressively seeking to expand its $400
million medical diagnostics business.  For example, Du Pont is
one of five companies that recently have filed with the Food
and Drug Administration to do field work on a diagnostic test
for AIDS, or acquired immune deficiency syndrome.
   "There are markets out there with real needs where we
don't have to displace anyone," David D. Mooberry, group vice
president of biomedical products, said.

[This article is made available here by Dow Jones Co. for the 
personal and non-commercial use of callers to this bbs, in the 
hope that it will be of some help to those who are suffering 
from the disease and others who are seeking to help them.]